贝那普利联合环磷腺苷葡胺治疗充血性心力衰竭的疗效

Therapeutic results of benazepril and meglumine adenosine cyclophosphate on congestive heart failure

目的:观察贝那普利联合环磷腺苷葡胺治疗充血性心力衰竭(CHF)的临床疗效。方法:243例CHF患者被随机分为对照组(81例,常规治疗)、治疗1组(80例,常规治疗基础上加贝那普利)、治疗2组(82例,常规治疗基础上加贝那普利和环磷腺苷葡胺)。疗程为14d。分别于用药前及给药14 d后测定血浆B型利钠肽(BNP)浓度、左室射血分数(LVEF)、左室短轴缩短率(FS)及心脏指数(CI)。结果:与对照组比较,治疗组LVEF、FS、CI显著改善(P均<0.05),血浆BNP浓度显著降低(P<0.05),治疗2组与治疗1组相比血浆BNP浓度进一步降低(P<0.05),心功能无进一步改善。结论:贝那普利可改善CHF患者心功能,降低血浆BNP浓度,联合环磷腺苷葡胺能进一步降低血浆BNP浓度,治疗CHF疗效显著。

Objective： To investigate the therapeutic results of benazepril and meglumine adenosine cyclophosphate on congestive heart failure （CHF）. Methods： A total of 243 patients were randomly divided into control group （81 cases, acceptcd routine therapy） and the first treatment group （80 cases, accepted routine therapy and Benazepril）, the second treatment group （82 cases, accepted routine therapy and benazepril plus meglumine adenosine eyclophosphate）, all treated for 14 days. LVEF （left ventricular ejection fraction）, FS （left ventricular fractional shortening） and CI （cardiac index） by echocardiography and plasma BNP level were evaluated before and after 14 days therapy. Results.. After 14 days therapy, compared with control group, the LVEF, FS, CI significantly improved （P〈0.05 all）, BNP level significantly decreased （P〈0.05） in all treatment groups; compared to the first treatment group the second one had more lower BNP level （P〈0. 05）. Conclusion： Benazepril may markedly decline BNP level, and improve patients＇ cardiac function, combined with meglumine adenosine cyclophosphate may decline BNP level more for CHF patients.